Boston in June was buzzing with the vibrant energy of the biotech industry.
JNPMEDI attended both the K-BioX Summit and BIO International Convention 2025 (BIO USA 2025), engaging in diverse discussions and exploring potential collaborations at the intersection of domestic and international bio ecosystems.
JongHyun Park, Head of the Global Research Center, and Jung Kim, VC Principal, were part of the trip. As an AI-based clinical trial consulting firm, JNPMEDI held in-depth discussions with numerous partners, focusing on its technological capabilities and global expansion strategies.
K-BioX Summit - Spotlighting Korean Biotech in Boston
On June 15, the K-BioX Summit, held at the Simches Research Center in the Mass General Hospital (MGH), was co-hosted by Chuncheon City, KAMC (Korean Association of Medical Colleges), Rutgers University, and K-BioX. This event was designed to directly connect the technological capabilities and research achievements of Korea’s bio industry with international experts and organizations.
Beyond presentations and panel discussions, active networking sessions were also held. JNPMEDI engaged in in-depth discussions with Gangwon Technopark, the Chuncheon Bioindustry Promotion Agency, and Chuncheon City to enhance the competitiveness of Gangwon Province's pharmaceutical and bio industries and identify collaboration opportunities. This exchange is expected to lay a concrete foundation for vitalizing the regional bio ecosystem.
Most importantly, it was a highly meaningful time as Korean companies could meet directly on-site to share their challenges and visions, fostering valuable exchange. JNPMEDI, which supports Korean bio companies' global expansion by combining digital technology with clinical expertise, also garnered significant interest at the event.
BIO USA 2025 - JNPMEDI in the Global Market
From June 16 to 19, JNPMEDI participated in BIO USA 2025, held at the Boston Convention Center.
At this global gathering of pharmaceutical companies, biotech firms, medtech firms, research institutions, and investors from around the world, JNPMEDI focused on introducing its core technologies, including the Maven Clinical Cloud, and its global expansion strategies.
JNPMEDI garnered significant interest by showcasing its global clinical and regulatory support system, including DM, STAT, and PV services offered through its Global Delivery Center (GDC), and proprietary software like Maven CDMS, Maven Converter, and Maven Safety. Enquiries about digital clinical platforms were active on-site, providing direct insight into global market trends such as AI-powered clinical platforms, real-world data-driven research, and country-specific regulatory changes.
Connecting, Conversing, and Preparing for What's Next
In Boston, JNPMEDI engaged with various partners, leveraging its technology and service operation experience. The company identified numerous potential collaboration points that could lead to concrete partnerships. This trip was more than just event attendance; it was a meaningful opportunity to solidify collaboration with domestic institutions on the global stage and explore tangible cooperation possibilities with global partners.
JNPMEDI will continue to innovate clinical trial operations through digital technology, consistently striving to shape the future of the bio industry alongside a growing number of global partners.
Boston in June was buzzing with the vibrant energy of the biotech industry.
JNPMEDI attended both the K-BioX Summit and BIO International Convention 2025 (BIO USA 2025), engaging in diverse discussions and exploring potential collaborations at the intersection of domestic and international bio ecosystems.
JongHyun Park, Head of the Global Research Center, and Jung Kim, VC Principal, were part of the trip. As an AI-based clinical trial consulting firm, JNPMEDI held in-depth discussions with numerous partners, focusing on its technological capabilities and global expansion strategies.
K-BioX Summit - Spotlighting Korean Biotech in Boston
On June 15, the K-BioX Summit, held at the Simches Research Center in the Mass General Hospital (MGH), was co-hosted by Chuncheon City, KAMC (Korean Association of Medical Colleges), Rutgers University, and K-BioX. This event was designed to directly connect the technological capabilities and research achievements of Korea’s bio industry with international experts and organizations.
Beyond presentations and panel discussions, active networking sessions were also held. JNPMEDI engaged in in-depth discussions with Gangwon Technopark, the Chuncheon Bioindustry Promotion Agency, and Chuncheon City to enhance the competitiveness of Gangwon Province's pharmaceutical and bio industries and identify collaboration opportunities. This exchange is expected to lay a concrete foundation for vitalizing the regional bio ecosystem.
Most importantly, it was a highly meaningful time as Korean companies could meet directly on-site to share their challenges and visions, fostering valuable exchange. JNPMEDI, which supports Korean bio companies' global expansion by combining digital technology with clinical expertise, also garnered significant interest at the event.
BIO USA 2025 - JNPMEDI in the Global Market
From June 16 to 19, JNPMEDI participated in BIO USA 2025, held at the Boston Convention Center.
At this global gathering of pharmaceutical companies, biotech firms, medtech firms, research institutions, and investors from around the world, JNPMEDI focused on introducing its core technologies, including the Maven Clinical Cloud, and its global expansion strategies.
JNPMEDI garnered significant interest by showcasing its global clinical and regulatory support system, including DM, STAT, and PV services offered through its Global Delivery Center (GDC), and proprietary software like Maven CDMS, Maven Converter, and Maven Safety. Enquiries about digital clinical platforms were active on-site, providing direct insight into global market trends such as AI-powered clinical platforms, real-world data-driven research, and country-specific regulatory changes.
Connecting, Conversing, and Preparing for What's Next
In Boston, JNPMEDI engaged with various partners, leveraging its technology and service operation experience. The company identified numerous potential collaboration points that could lead to concrete partnerships. This trip was more than just event attendance; it was a meaningful opportunity to solidify collaboration with domestic institutions on the global stage and explore tangible cooperation possibilities with global partners.
JNPMEDI will continue to innovate clinical trial operations through digital technology, consistently striving to shape the future of the bio industry alongside a growing number of global partners.